NYSE:YUM
NYSE:YUMHospitality

Yum Brands (YUM) Valuation Check After Latest Annual Revenue And Earnings Update

Yum! Brands (YUM) continues to attract attention after posting annual revenue of US$8.1b and net income of US$1.4b, prompting investors to reassess the fast food group’s recent share performance and value score. See our latest analysis for Yum! Brands. Yum! Brands’ recent results come after a period where the share price has moved to US$150.49, with a 30 day share price return of 3.81%, while the 1 year total shareholder return stands at 17.85%, suggesting momentum has been broadly...
NasdaqCM:SBET
NasdaqCM:SBETHospitality

Assessing SharpLink Gaming (SBET) Valuation As iGaming And Ethereum Staking Model Draws Fresh Attention

Without a fresh headline to point to, SharpLink Gaming (SBET) is drawing attention for its mix of affiliate marketing for sportsbooks and online casinos alongside an Ethereum staking business model. See our latest analysis for SharpLink Gaming. The recent 1 day share price return of 8.39% to US$9.69 stands against a 30 day share price return of 9.61% decline and a 90 day share price return of 45.47% decline, while the 1 year total shareholder return of 22.54% contrasts sharply with a 3 year...
NasdaqGM:STAA
NasdaqGM:STAAMedical Equipment

Assessing STAAR Surgical (STAA) Valuation As Sentiment Cools And Revenue Growth Assumptions Tighten

STAAR Surgical (STAA) has come into focus after a recent move in its share price, with the stock last closing at US$23.60 and showing mixed returns over the past year and the past 3 months. See our latest analysis for STAAR Surgical. The latest 1 day share price return of 2.21% comes after a weaker 30 day share price return of 7.01% decline and a 3 year total shareholder return of 63.94% decline, suggesting momentum has been fading rather than building recently. If STAAR Surgical has you...
NYSE:TPL
NYSE:TPLOil and Gas

Data Center Pivot and Stock Split Could Be A Game Changer For Texas Pacific Land (TPL)

Texas Pacific Land Corp recently announced a partnership with Bolt Data & Energy to develop large-scale data center campuses across its land holdings, committing a US$50,000,000 investment alongside an equity stake, while also setting December 22, 2025, as the date for a previously declared three-for-one stock split. This move signals an effort to extend the company’s land and infrastructure monetization beyond oil and gas royalties, adding exposure to digital infrastructure development on...
NasdaqGS:MORN
NasdaqGS:MORNCapital Markets

Assessing Morningstar (MORN) Valuation After Recent Share Price Weakness And DCF Fair Value Signals

Morningstar (MORN) has drawn investor attention after recent share price weakness, with the stock down about 3% over the past month and 7% in the past 3 months from its last close of $210.42. See our latest analysis for Morningstar. That recent 1 month share price return of 3.57% and 3 month share price return of 7% sit against a 1 year total shareholder return of 34.79% and 5 year total shareholder return of 4.11%. This suggests momentum has faded compared with the longer run. If this...
NYSE:LNN
NYSE:LNNMachinery

A Look At Lindsay (LNN) Valuation After Mixed Earnings And International Irrigation Growth

Mixed earnings reaction puts Lindsay in focus Lindsay (LNN) recently reported quarterly results, with revenue slightly ahead of analyst expectations but a significant shortfall on adjusted operating income, alongside strong international irrigation performance and a subsequent decline in the share price. See our latest analysis for Lindsay. At a share price of $121.15, Lindsay has seen short term price weakness reflected in a 90 day share price return of a 12.94% decline, while the 1 year...
NasdaqGM:ALVO
NasdaqGM:ALVOBiotechs

A Look At Alvotech (ALVO) Valuation After New US$100 Million Term Loan To Fund Biosimilar Pipeline

Alvotech (NasdaqGM:ALVO) secured a new US$100 million senior term loan led by GoldenTree Asset Management, intended to support its 30-product biosimilar pipeline and four planned global launches through 2026. See our latest analysis for Alvotech. Despite the fresh US$100 million financing and earlier refinancing steps, Alvotech’s share price return over the past 90 days has declined 42.13%, and its 1 year total shareholder return of 62.41% decline points to fading momentum even with the...
NasdaqGM:ASST
NasdaqGM:ASSTCapital Markets

A Look At Strive Asset Management (ASST) Valuation After Recent Short Term Share Price Momentum

Strive Asset Management (ASST) has drawn investor attention after recent trading, with the stock last closing at US$0.86. Short term moves contrast with weaker returns over the past 3 months, prompting closer scrutiny of fundamentals. See our latest analysis for Strive Asset Management. The 1 day share price return of 17.15% and 7 day share price return of 11.79% sit against a 90 day share price return decline of 58.83%, suggesting short term momentum is building after a weak few months...
NasdaqGS:POOL
NasdaqGS:POOLRetail Distributors

A Look At Pool Corp (POOL) Valuation As Growth Slows And North American Demand Comes Into Focus

Recent commentary around Pool (POOL) has focused on cooling demand as household budgets tighten. This has raised questions about how the pool supplier can reinvigorate growth when roughly 95% of its revenue still depends on North American customers. See our latest analysis for Pool. Pool’s share price has softened in recent months, with a 90 day share price return of 23.71% and a 1 year total shareholder return of 29.78%. This suggests momentum has faded as investors reassess growth and risk...
NYSE:GRMN
NYSE:GRMNConsumer Durables

Has Garmin (GRMN) Fallen Enough After Flat Year To Look Attractive Again?

If you are wondering whether Garmin's current share price lines up with its underlying worth, this article is designed to walk you through the pieces that matter most. Garmin's share price closed at US$202.44, with a 1.5% decline over the last 7 days, a 0.6% decline over the last 30 days, and a 1% decline over the last year. The 3 year and 5 year returns are 118.9% and 86.1% respectively, and the year to date return sits at 0.0%. Those moves have put valuation questions back on the radar for...
NYSE:RMD
NYSE:RMDMedical Equipment

ResMed (RMD) Valuation Check As Investors Await Fiscal Q2 Earnings Update

ResMed (RMD) is back in focus as the company approaches its fiscal second quarter 2026 earnings release, with analysts watching closely after several quarters of topping Wall Street earnings expectations. See our latest analysis for ResMed. At a latest share price of $244.81, ResMed’s 90 day share price return of a 13.58% decline contrasts with a 1 year total shareholder return of 5.06% and a 3 year total shareholder return of 20.05%. This suggests recent momentum has faded even as longer...
NYSE:KR
NYSE:KRConsumer Retailing

Kroger’s Expanded US$9.5 Billion Buyback Plan Might Change The Case For Investing In KR

In December 2025, Kroger completed a major share repurchase phase, buying back about 14.2% of its stock for roughly US$6.60 billion, and on December 23, 2025, the company lifted its total buyback authorization to about US$9.50 billion. This sizable increase in repurchase capacity highlights Kroger’s ongoing commitment to returning cash to shareholders while it reshapes its e-commerce and fulfillment model. We’ll now explore how Kroger’s expanded buyback authorization and continued...
NYSE:BWA
NYSE:BWAAuto Components

How Investors Are Reacting To BorgWarner (BWA) Balancing Higher 2025 Guidance With A Cautious EV Outlook

Morgan Stanley previously lowered its rating on BorgWarner to Equal Weight while the company simultaneously raised its 2025 financial performance estimates, citing higher industrial production and favorable foreign exchange despite ongoing production delays in North America and Europe. The combination of a cautious outlook for electric vehicles through 2026 and management’s improved near-term guidance highlights BorgWarner’s reliance on internal combustion and hybrid powertrains as a key...
NYSE:HESM
NYSE:HESMOil and Gas

Is Raymond James' Downgrade and Chevron-tied Board Shift Altering The Investment Case For Hess Midstream (HESM)?

Recently, Raymond James cut its rating on Hess Midstream from Outperform to Market Perform, citing limited near-term growth prospects, while the company also reshaped its board after director Andrew B. Walz resigned to become an executive officer at Chevron. This combination of a cooler analyst view and governance changes tied to Chevron’s influence raises fresh questions about Hess Midstream’s medium-term growth path and independence. Next, we’ll examine how Raymond James’ downgrade,...
NasdaqGS:CALM
NasdaqGS:CALMFood

Assessing Cal-Maine Foods (CALM) Valuation After Recent Share Price Weakness

Cal-Maine Foods (CALM) has recently drawn attention after a period of weaker share performance, with the stock down over the past week, month, past 3 months and year. This has prompted investors to reassess its current valuation. See our latest analysis for Cal-Maine Foods. The recent 4.4% 7 day share price decline and 15.5% 3 month share price pullback come against a 1 year total shareholder return of an 18.2% decline, but a much stronger 3 and 5 year total shareholder return. This suggests...
NYSE:RNR
NYSE:RNRInsurance

A Look At RenaissanceRe Holdings (RNR) Valuation After Recent Share Price Volatility

RenaissanceRe Holdings (NYSE:RNR) is back on investors’ radar after recent share price moves, with the stock closing at US$272.24. That puts its 1 year total return at 10.2% and its past 3 months performance at 2.0%. See our latest analysis for RenaissanceRe Holdings. Recent trading has been a bit choppy, with a 1 day share price return of 3.17% decline and a 7 day share price return of 4.09% decline. That sits against a 1 year total shareholder return of 10.2% and a 5 year total shareholder...
NasdaqCM:SKYT
NasdaqCM:SKYTSemiconductor

Why SkyWater Technology (SKYT) Is Up 21.6% After Strong Texas-Fueled Q4 Revenue Outlook

In recent days, SkyWater Technology reported strong performance from its newly acquired Texas operation and guided fourth-quarter revenue to a US$155 million–US$165 million range, ahead of its February earnings release. An important angle for investors is how this Texas facility appears to be contributing meaningfully to near-term revenue visibility and operational scale. We’ll now examine how the stronger-than-expected contribution from the Texas acquisition could influence SkyWater...
NYSE:SHW
NYSE:SHWChemicals

Assessing Sherwin-Williams (SHW) Valuation As Pricing Power And Cost Discipline Meet Key Earnings Test

Recent analyst commentary around Sherwin-Williams (SHW) has highlighted the company’s pricing power, brand strength, and cost discipline, with investors now looking to the upcoming earnings release as a key test of those themes. See our latest analysis for Sherwin-Williams. At a share price of $327.84, Sherwin-Williams has seen short term share price returns move slightly in both directions recently, while its 3 year total shareholder return of 42.72% contrasts with a slightly negative 1 year...
NasdaqGS:RUN
NasdaqGS:RUNElectrical

Sunrun’s Cash Flow And Storage Gains Might Change The Case For Investing In Sunrun (RUN)

In Q3 2025, Sunrun Inc. reported a revenue increase of 35% year over year, a 10% rise in aggregate subscriber value, strong storage adoption, and six consecutive quarters of positive cash flow, supported by US$709 million in unrestricted cash and ongoing access to capital markets. This combination of improving cash generation and storage-led unit economics has strengthened the perception of Sunrun’s business model resilience and long-term value creation potential. Next, we’ll examine how...
NYSE:KO
NYSE:KOBeverage

Coca-Cola (KO) Valuation Check After Recent Share Price Softness

Why Coca-Cola stock is on investors’ radar today Coca-Cola (KO) is back in focus after recent trading left the shares with a 1.1% one day decline and slightly lower performance over the past week and month, despite a positive past 3 months. See our latest analysis for Coca-Cola. Zooming out, Coca-Cola’s recent share price softness contrasts with a 1-year total shareholder return of 17.0% and a 5-year total shareholder return of 60.0%. This suggests longer term momentum remains positive even...
NYSE:MIR
NYSE:MIRElectronic

A Look At Mirion Technologies (MIR) Valuation After Its Earnings Beat And Nuclear Power Segment Strength

Mirion Technologies (MIR) has drawn fresh attention after reporting quarterly earnings per share ahead of expectations, along with strong performance in its nuclear power end market, yet the stock has retreated following the announcement. See our latest analysis for Mirion Technologies. The latest earnings news arrives after a mixed stretch in the share price, with a 3.03% 90 day share price return and a 36.25% 1 year total shareholder return suggesting long term momentum, while shorter term...
NYSE:RDN
NYSE:RDNDiversified Financial

A Look At Radian Group (RDN) Valuation As Shares Trade Near Recent Levels

Radian Group (RDN) is back on investors’ radar after recent share price moves. The stock last closed at $35.92, prompting fresh questions about how its mortgage and real estate services business is currently valued. See our latest analysis for Radian Group. While the latest move to $35.92 comes with a modest 1-day share price return of 0.19% decline and a 7-day share price return of 0.99% decline, the share price return over the last 30 and 90 days has been positive. Over the longer term,...
NasdaqGS:MLYS
NasdaqGS:MLYSBiotechs

Is JAMA-Lauded Launch-HTN And FDA Feedback Altering The Investment Case For Mineralys Therapeutics (MLYS)?

Mineralys Therapeutics recently advanced its aldosterone synthase inhibitor program as the Phase 3 Launch-HTN trial of Lorundrostat, which showed significant reductions in systolic blood pressure in treatment-resistant hypertension, was recognized in JAMA’s inaugural “Research of the Year,” and the company received FDA pre-NDA feedback supporting a planned New Drug Application submission. This recognition, combined with the prospect of additional Lorundrostat trial readouts expected in 2026,...
NasdaqCM:DCTH
NasdaqCM:DCTHMedical Equipment

Will New HEPZATO KIT Subgroup Data on Tumor Burden and Survival Change Delcath Systems' (DCTH) Narrative

Delcath Systems recently reported publication of subgroup analyses from its phase 3 FOCUS study of the HEPZATO KIT for unresectable metastatic uveal melanoma in the Journal of Cancer Research and Clinical Oncology, detailing efficacy and safety outcomes across multiple patient categories. The data highlight that patients with lower tumor burden and low or normal LDH experienced meaningfully longer progression-free and overall survival, with many responses emerging only after several...